Compare Monolithic Power Systems Inc (MPWR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Organon & Co. Common Stock — how do they compare? Monolithic Power Systems Inc trades at $1,239 (market cap $64.85B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Monolithic Power Systems Inc is far larger — about 17.9× Organon & Co. Common Stock's market cap, and Monolithic Power Systems Inc pays the higher dividend (0.61%). Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Organon & Co. Common Stock for 0 Days on average.
| MPWR | OGN | |
|---|---|---|
Market Cap | $64.85B | $3.62B |
Volume | 692,538 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $1.69K | $13.81 |
52-Week Low | $856.96 | $5.70 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $63.45B | $11.04B |
Dividend Yield | 0.61% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,319.55 with minimal daily movement (+0.02%) amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, 24.5% net margins, and robust revenue growth from $2.8B to $3.3B year-over-year. Recent news highlights CEO share sales and a manufacturing partnership with GlobalFoundries to support AI and data center demand. Valuation remains elevated with P/E at 80.5 and P/S at 19.7, reflecting high growth expectations.
The outlook remains positive given analyst consensus (88% buy ratings) and a $1,830 price target, but risks include premium valuation compression, insider selling, and dependence on AI infrastructure growth. Cash flow strength supports dividend payments, though technical weakness near key support at $1,300 requires monitoring for sustained bullish momentum.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
